Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Bristol-Myers Squibb Company (BMY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 98,007,016
  • Shares Outstanding, K 1,634,540
  • Annual Sales, $ 20,776 M
  • Annual Income, $ 1,007 M
  • 36-Month Beta 1.02
  • Price/Sales 4.67
  • Price/Cash Flow 16.86
  • Price/Book 7.81

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate 0.89
  • Number of Estimates 6
  • High Estimate 0.93
  • Low Estimate 0.86
  • Prior Year 0.75
  • Growth Rate Est. (year over year) +18.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
55.45 +8.13%
on 07/23/18
60.99 -1.69%
on 07/26/18
+3.10 (+5.45%)
since 07/13/18
3-Month
49.97 +19.99%
on 06/04/18
60.99 -1.69%
on 07/26/18
+7.94 (+15.26%)
since 05/14/18
52-Week
49.96 +20.02%
on 05/08/18
70.05 -14.40%
on 02/16/18
+2.34 (+4.06%)
since 08/14/17

Most Recent Stories

More News
Global Liver Cancer Drugs Market Report 2016-2022 - Key Players are Bayer, Bristol-Myers Squibb, Eisai, and Exelixis

The "Liver Cancer Drugs Market Size, Share & Trends Analysis Report By Therapeutic Class (Targeted Therapy, Immunotherapy), By Country (U.S., Japan, U.K., Germany, Spain, Italy, France), And Segment Forecasts,...

BMY : 59.96 (+0.91%)
5 Top-Ranked S&P 500 Stocks to Buy on Market Dip

As the long term picture is rosy after the initial dip, it will be wise to invest in growth stocks. Also, stocks after a dip are at a discount.

AAP : 156.13 (+7.79%)
A : 66.75 (+1.23%)
DHI : 43.99 (+1.08%)
CAT : 134.92 (-0.07%)
BMY : 59.96 (+0.91%)
Zacks.com featured highlights include: United States Cellular, Molina Healthcare, Archer Daniels, Bristol-Myers and Callaway Golf

Zacks.com featured highlights include: United States Cellular, Molina Healthcare, Archer Daniels, Bristol-Myers and Callaway Golf

ELY : 22.62 (+1.34%)
MOH : 133.92 (+1.43%)
ADM : 49.94 (+1.26%)
USM : 43.47 (+0.65%)
BMY : 59.96 (+0.91%)
Pick These 5 Stocks With Remarkable Relative Price Strength

Want to try an out-of-the-box approach to earn handsome returns? Tap these stocks with explosive relative price strength.

ELY : 22.62 (+1.34%)
MOH : 133.92 (+1.43%)
ADM : 49.94 (+1.26%)
USM : 43.47 (+0.65%)
BMY : 59.96 (+0.91%)
The Zacks Analyst Blog Highlights: Novo Nordisk, J&J, Allergan, Editas, AstraZeneca, Merck and Bristol-Myers

The Zacks Analyst Blog Highlights: Novo Nordisk, J&J, Allergan, Editas, AstraZeneca, Merck and Bristol-Myers

AZN : 38.98 (-0.10%)
NVO : 48.35 (+2.22%)
JNJ : 129.50 (-0.55%)
MRK : 66.46 (-0.39%)
AGN : 184.46 (+0.10%)
EDIT : 29.60 (+0.82%)
BMY : 59.96 (+0.91%)
Intrexon Reports Preliminary Earnings and Revenues for Q2

Intrexon (XON) reports preliminary second-quarter 2018 results and expects a loss of 17 cents for the quarter.

XON : 14.19 (+0.64%)
ZIOP : 2.71 (-5.90%)
FCSC : 2.06 (-2.83%)
BMY : 59.96 (+0.91%)
Pharma Stock Roundup: NVO Q2 Earnings, JNJ, AGN & AZN's Pipeline Updates in Focus

Novo Nordisk (NVO) reports strong Q2 results. J&J (JNJ) seeks approval for new dosing regimen of multiple myeloma drug. Allergan (AGN) exercises option to buy Editas' lead ocular candidate.

AZN : 38.98 (-0.10%)
NVO : 48.35 (+2.22%)
JNJ : 129.50 (-0.55%)
MRK : 66.46 (-0.39%)
AGN : 184.46 (+0.10%)
EDIT : 29.60 (+0.82%)
BMY : 59.96 (+0.91%)
Celldex (CLDX) Q2 Earnings and Revenues Surpass Estimates

Celldex (CLDX) reports narrower-than-expected loss in Q2. Revenues fell due to reduced contract revenues.

CLDX : 0.43 (+2.38%)
LLY : 102.44 (unch)
SGEN : 74.63 (+1.12%)
BMY : 59.96 (+0.91%)
Nektar (NKTR) Q2 Earnings In Line, Product Sales Down Y/Y

Nektar's (NKTR) second-quarter earnings meet estimates. Although revenues soar on one-time payment from Bristol-Myers, product sales fall. Shares down.

LLY : 102.44 (unch)
SGEN : 74.63 (+1.12%)
BMY : 59.96 (+0.91%)
NKTR : 60.39 (+1.82%)
Infinity (INFI) Posts Narrower-Than-Expected Loss in Q2

Infinity (INFI) posts narrower-than-expected loss in the second quarter of 2018 and provides update on pipeline candidate, IPI 549.

VRTX : 175.93 (+0.50%)
RCUS : 12.29 (+3.80%)
INFI : 2.07 (+4.55%)
BMY : 59.96 (+0.91%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade BMY with:

Business Summary

Bristol-Myers Squibb is a differentiated company, led by their unique BioPharma strategy that leverages the reach and resources of a major pharma company paired with the entrepreneurial spirit and agility of a biotech firm. They work every day to deliver innovative medicines for patients with serious...

See More

Key Turning Points

2nd Resistance Point 60.64
1st Resistance Point 60.30
Last Price 59.96
1st Support Level 59.46
2nd Support Level 58.96

See More

52-Week High 70.05
Fibonacci 61.8% 62.38
Fibonacci 50% 60.01
Last Price 59.96
Fibonacci 38.2% 57.63
52-Week Low 49.96

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar